PRAX vs. ETNB, OPK, ARQT, ALXO, SPRY, ABVX, OCUL, IMNM, ZNTL, and TYRA
Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include 89bio (ETNB), OPKO Health (OPK), Arcutis Biotherapeutics (ARQT), ALX Oncology (ALXO), ARS Pharmaceuticals (SPRY), ABIVAX Société Anonyme (ABVX), Ocular Therapeutix (OCUL), Immunome (IMNM), Zentalis Pharmaceuticals (ZNTL), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical preparations" industry.
89bio (NASDAQ:ETNB) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
89bio has a net margin of 0.00% compared to 89bio's net margin of -5,037.88%. Praxis Precision Medicines' return on equity of -35.66% beat 89bio's return on equity.
In the previous week, 89bio and 89bio both had 15 articles in the media. 89bio's average media sentiment score of 0.17 beat Praxis Precision Medicines' score of 0.02 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.
Praxis Precision Medicines has higher revenue and earnings than 89bio. 89bio is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
89bio received 71 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. However, 62.50% of users gave Praxis Precision Medicines an outperform vote while only 62.34% of users gave 89bio an outperform vote.
89bio presently has a consensus target price of $28.71, indicating a potential upside of 218.69%. Praxis Precision Medicines has a consensus target price of $105.80, indicating a potential upside of 128.61%. Given Praxis Precision Medicines' higher possible upside, research analysts clearly believe 89bio is more favorable than Praxis Precision Medicines.
89bio has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500.
67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.8% of 89bio shares are held by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
89bio and Praxis Precision Medicines tied by winning 8 of the 16 factors compared between the two stocks.
Get Praxis Precision Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Praxis Precision Medicines Competitors List
Related Companies and Tools
